Ulcerative Colitis Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Ulcerative Colitis 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la tes t  repor t  by  IMARC Group ,  t i t l ed  "Ulcera t ive  Co l i t i s  
Market :  Globa l  Industry  Trends,  Share ,  S ize ,  Growth,  Oppor tun i ty  and 
Forecast  2024 -2032 ,"  t he  g loba l  u lce ra t i ve  co l i t i s  marke t  s ize  reached  US$ 
7 .8  B i l l ion  in  2023 .
Report Factors Af fect ing the Growth of  the Ulcerat ive Col i t is  Industry:
Increasing Prevalence of  Ulcerat ive Col i t is
Highlight and The g rowth  o f  the  u lce ra t ive  co l i t i s  i ndus t ry  i s  s ign i f i can t ly  d r iven  by  the  
inc reas ing  p reva lence  o f  t he  d i sease  wor ldwide .  Fac to rs  such  as  chang ing  
l i f es ty les ,  d ie ta ry  hab i ts ,  and  gene t i c  p red ispos i t ion  con t r ibu te  to  the  r i s ing  
Description i nc idence  o f  u l ce ra t i ve  co l i t i s .  
Th is  ch ron ic  in f lammatory  bowe l  d i sease  a f fec ts  a  subs tan t ia l  po r t ion  o f  t he  
popu la t ion ,  lead ing  to  a  g row ing  demand fo r  e f fec t ive  t rea tments .  The  h ighe r  
p reva lence  boos ts  the  need  fo r  ex is t ing  the rap ies  and  s t imu la tes  research  and  
deve lopment  e f fo r ts  to  d iscover  new and  innova t ive  t rea tments ,  d r iv ing  ove ra l l  
marke t  g rowth .
Advancements in Treatment Options
Advancements  in  t reatment  opt ions a re  a  c ruc ia l  fac to r  p rope l l ing  the  g rowth  
o f  the  u lcera t i ve  co l i t i s  indust ry .  Recent  years  have seen s ign i f i cant  
progress in  the  deve lopment  o f  b io log ics ,  sma l l  mo lecu les ,  and persona l ized  
Report medic ine approaches  tha t  o f fe r  be t ter  e f f icacy and  safe ty  p ro f i les  compared  
to  t rad i t iona l  therap ies .  
Highlight and Innovat ions such  as  ta rge ted  therap ies  and  immunomodula to rs  a re  prov id ing 
improved  symptom management  and  d isease  cont ro l  fo r  pat ients .  These  
Description advancements  a re  expand ing  the  therapeut ic  landscape,  increas ing  pa t ient  access  to  e f fec t i ve  t rea tments ,  and  d r iv ing  marke t  g rowth by  address ing  
unmet  medica l  needs.
Increasing Awareness and Diagnosis
Increas ing awareness  and  improved  d iagnos is  o f  u lce ra t i ve  co l i t i s  are  
s ign i f ican t ly  impact ing  the  indust ry ’s  g rowth.  Pub l i c  hea l th  in i t ia t i ves ,  
educa t iona l  p rograms,  and  advocacy  by  pa t ien t  organ iza t ions are  ra is ing  
awareness  about  the  d isease,  lead ing to  ear l ie r  d iagnos is  and  in te rven t ion.
Enhanced  d iagnos t ic  t echn iques ,  i nc lud ing  advanced  imag ing  and  b iomarke r  
iden t i f i ca t ion ,  enab le  more  accura te  and  t ime ly  de tec t ion  o f  u l ce ra t ive  co l i t i s .  
As  a  resu l t ,  mo re  pa t ien ts  a re  rece iv ing  appropr ia te  and  t ime ly  t rea tment ,  
wh ich  boos ts  the  demand fo r  u lce ra t ive  co l i t i s  t he rap ies .  Th is  he igh tened  
awareness  and  be t te r  d iagnos t ic  p rac t ices  ensure  tha t  more  pa t ien ts  rece ive  
Report the  ca re  they  need ,  d r iv ing  the  g rowth  o f  the  u lce ra t ive  co l i t i s  marke t .
Highlight and Request  for  a  PDF sample  o f  th is  repor t :  
h t tps : / /www. imarcgroup .com/u lce ra t i ve -co l i t i s -marke t / reques tsamp le
Description
Report Description
Global  Ulcerat ive Col i t is  Market  Trends:
The g lobal  u lcerat ive co l i t is  market  is  exper ienc ing notab le  growth dr iven by advancements  in  b io log ic  
therap ies  and personal ized medic ine approaches.  B io log ics  target ing spec i f ic  immune pathways have 
revo lu t ion ized t reatment  outcomes,  o f fer ing improved symptom management  and d isease cont ro l  for  
pat ients.  There is  a lso a  growing emphasis  on ear ly  d iagnos is  and in tervent ion,  fac i l i ta ted by enhanced 
d iagnost ic  technolog ies  and b iomarker  ident i f i ca t ion.  
Moreover ,  the market  is  w i tness ing increased pat ient -cent r ic  approaches,  w i th  therap ies  ta i lored to  
ind iv idual  genet ic  prof i les  and d isease character is t ics .  Regulatory  approvals for  novel  therap ies  and 
expanding t reatment  opt ions fur ther  cont r ibute to  market  growth.  These t rends re f lec t  a  sh i f t  toward more 
ef fec t ive and personal ized care parad igms in  u lcerat ive  co l i t i s  management ,  promis ing bet ter  qual i ty  o f  l i fe  
and outcomes for  pat ients  g lobal ly .
View Report  TOC,  F igures and Tables :  ht tps: / /www.imarcgroup.com/ulcerat ive-col i t is-market
Breakup by Type:
• Mild UC
• Moderate UC
• Severe UC
Breakup by Disease Type:
Report • Ulcerat ive Proct it is
• Proctosigmoidit is
Segmentation
• Left-s ided Col it is
• Pancol i t is  or  Universal Col i t is
• Fulminant  Coli t is
Breakup by Molecule Type:
• Small  Molecules
• Biologics
Breakup by Drug Type:
• Anti- Infl ammatory Drugs
• Anti-TNF Biologics
• Immunosuppressant
• Calcineurin Inhibitors
• Others
Report 
Segmentation Breakup by Route of Administration:
• Oral
• Injectable
Breakup by Distribution Channel:
• Hospital  Pharmacies
• Retai l  Pharmacies
• Drug Store
• Others
Breakup by Region:
• North America
Report 
• Asia-Pacifi c
Segmentation • Europe
• Latin America
• Middle East and Afr ica
• Abbott Laboratories
• AbbVie Inc.
• AstraZeneca plc
• Bristol -Myers Squibb Company
Competitive • El i  Li l ly and Company
• F. Hoff mann-La Roche Ltd.
Landscape 
• GlaxoSmithKl ine plc
with Key • Johnson & Johnson
Players • Merck & Co. Inc.
• Pfi zer Inc.
• Takeda Pharmaceutical  Company Limited
• Teva Pharmaceutical  Industr ies Ltd.
How has the global ulcerative colitis market performed 
so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in 
the global ulcerative colitis market?
What is the impact of each driver, restraint, and 
opportunity on the global ulcerative colitis market?
Key What are the key regional markets?
Questions Which countries represent the most attractive 
ulcerative colitis market?
Answered in 
What is the breakup of the market based on the type?
the Report
Which is the most attractive type in the ulcerative 
colitis market?
What is the breakup of the market based on the disease 
type?
Which is the most attractive disease type in the 
ulcerative colitis market?
What is the breakup of the market based on the 
molecule type?
Which is the most attractive molecule type in the 
ulcerative colitis market?
What is the breakup of the market based on the drug 
type?
Which is the most attractive drug type in the ulcerative 
colitis market?
Key 
What is the breakup of the market based on the route 
of administration?
Questions 
Which is the most attractive route of administration in 
Answered in the ulcerative colitis market?
the Report What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the 
ulcerative colitis market?
What is the competitive structure of the market?
Who are the key players/companies in the global 
ulcerative colitis market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  U l c e r a t i v e  C o l i t i s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  T y p e
    6 . 1     M i l d  U C
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     M o d e r a t e  U C
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     S e v e r e  U C
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  D i s e a s e  T y p e
       
    7 . 1     U l c e r a t i v e  P r o c t i t i s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     P r o c t o s i g m o i d i t i s
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     L e f t - s i d e d  C o l i t i s
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     P a n c o l i t i s  o r  U n i v e r s a l  C o l i t i s
        7 . 4 . 1  M a r k e t  T r e n d s
Table of         7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     F u l m i n a n t  C o l i t i s
        7 . 5 . 1  M a r k e t  T r e n d s
Contents         7 . 5 . 2  M a r k e t  F o r e c a s t8    M a r k e t  B r e a k u p  b y  M o l e c u l e  T y p e
    8 . 1     S m a l l  M o l e c u l e s
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     B i o l o g i c s
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  D r u g  T y p e
    9 . 1     A n t i - I n f l a m m a t o r y  D r u g s
        9 . 1 . 1  M a r k e t  T r e n d s
        9 . 1 . 2  M a r k e t  F o r e c a s t
    9 . 2     A n t i - T N F  B i o l o g i c s
        9 . 2 . 1  M a r k e t  T r e n d s
        9 . 2 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / u l c e r a t i v e - co l i t i s - m a r ke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: